News
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace.
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Vertex Pharmaceuticals has announced meaningful results from two Phase II studies of its therapeutic VX-548. It is a non opioid pain medication that promises results.
When Sekar Kathiresan’s brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.
Ginkgo Bioworks reported its 2021 financials today, and the $1.7 billion of stock-based compensation caught everyone’s attention.
Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.
CAR-T cell therapy is still a time-consuming and expensive process. But researchers may have just solved the turnaround-time challenge for CAR-T.
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.
Myeloid Therapeutics has signed an exclusive collaboration deal with Prime Medicine to leverage both companies’ technologies and discover cancer and autoimmune diseases treatments.
The man who many consider the father of synthetic insulin treatment for diabetes, as well as a founder of modern biotechnology- Dr. Arthur Riggs - died this week at the age of 82.
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,
The U.S. FDA placed a partial hold on CytoDyn’s HIV program and a full clinical hold on its COVID-19 program in the U.S.